Structures by: Mittapalli S.
Total: 49
(E)-N'-(3,5-dichloro-2-hydroxybenzylidene)isonicotinohydrazide
C13H9Cl2N3O2
IUCrJ (2017) 4, 6 812-823
a=8.0683(4)Å b=10.7464(6)Å c=15.6155(8)Å
α=90° β=90.890(2)° γ=90°
(E)-N'-(3,5-dichloro-2-hydroxybenzylidene)isonicotinohydrazide
C13H9Cl2N3O2
IUCrJ (2017) 4, 6 812-823
a=15.441(3)Å b=8.3179(16)Å c=10.6014(18)Å
α=90° β=90° γ=90°
(E)-N'-(3,5-dichloro-2-hydroxybenzylidene)isonicotinohydrazide
C13H9Cl2N3O2
IUCrJ (2017) 4, 6 812-823
a=8.6916(6)Å b=10.2641(7)Å c=15.4965(10)Å
α=90° β=90.186(2)° γ=90°
(E)-N'-(3,5-dibromo-2-hydroxybenzylidene)isonicotinohydrazide
C13H9Br2N3O2
IUCrJ (2017) 4, 6 812-823
a=8.266(2)Å b=10.917(2)Å c=15.734(3)Å
α=90.00(3)° β=95.82(3)° γ=90.00(3)°
(E)-N'-(3,5-dibromo-2-hydroxybenzylidene)isonicotinohydrazide
C13H9Br2N3O2
IUCrJ (2017) 4, 6 812-823
a=9.8084(7)Å b=10.7751(8)Å c=13.9516(9)Å
α=103.219(3)° β=94.907(3)° γ=91.018(3)°
(E)-N'-(3-bromo-5-chloro-2-hydroxybenzylidene)isonicotinohydrazide
C13H9BrClN3O2
IUCrJ (2017) 4, 6 812-823
a=8.2475(9)Å b=10.8035(11)Å c=15.7971(15)Å
α=90° β=96.098(3)° γ=90°
(E)-N'-(3-bromo-5-chloro-2-hydroxybenzylidene)isonicotinohydrazide
C13H9BrClN3O2
IUCrJ (2017) 4, 6 812-823
a=8.651(2)Å b=10.446(3)Å c=15.680(4)Å
α=90° β=94.116(11)° γ=90°
(E)-N'-(3,5-diiodo-2-hydroxybenzylidene)isonicotinohydrazide
C13H9I2N3O2
IUCrJ (2017) 4, 6 812-823
a=8.2946(5)Å b=11.2673(6)Å c=16.2177(10)Å
α=90° β=97.993(2)° γ=90°
(E)-N'-(3,5-difluoro-2-hydroxybenzylidene)isonicotinohydrazide
C13H9F2N3O2
IUCrJ (2017) 4, 6 812-823
a=7.897(2)Å b=10.396(2)Å c=14.989(3)Å
α=90.00(3)° β=92.27(3)° γ=90.00(3)°
C6H8N2O2S,C6H11NO
C6H8N2O2S,C6H11NO
IUCrJ (2015) 2, 4 389-401
a=7.2731(4)Å b=15.9052(10)Å c=12.7766(6)Å
α=90.00° β=99.291(5)° γ=90.00°
C6H7NO2S,C7H13NO
C6H7NO2S,C7H13NO
IUCrJ (2015) 2, 4 389-401
a=7.3020(9)Å b=17.189(2)Å c=12.2835(16)Å
α=90.00° β=106.760(2)° γ=90.00°
C6H6ClNO2S,C6H11NO
C6H6ClNO2S,C6H11NO
IUCrJ (2015) 2, 4 389-401
a=7.1564(13)Å b=13.369(2)Å c=15.276(3)Å
α=90.00° β=90.00° γ=90.00°
C6H8N2O2S,C6H11NO
C6H8N2O2S,C6H11NO
IUCrJ (2015) 2, 4 389-401
a=7.0957(6)Å b=13.1280(13)Å c=15.3425(18)Å
α=90.00° β=90.00° γ=90.00°
C6H6BrNO2S,C6H11NO
C6H6BrNO2S,C6H11NO
IUCrJ (2015) 2, 4 389-401
a=7.156(3)Å b=13.538(5)Å c=15.406(6)Å
α=90.00° β=90.00° γ=90.00°
C6H6ClNO2S,C6H11NO
C6H6ClNO2S,C6H11NO
IUCrJ (2015) 2, 4 389-401
a=9.8782(6)Å b=14.1720(6)Å c=10.8753(6)Å
α=90.00° β=112.850(7)° γ=90.00°
C7H9NO2S,C5H9NO
C7H9NO2S,C5H9NO
IUCrJ (2015) 2, 4 389-401
a=5.3367(6)Å b=15.9206(17)Å c=16.070(3)Å
α=90.00° β=98.308(12)° γ=90.00°
C6H7NO2S,C6H11NO
C6H7NO2S,C6H11NO
IUCrJ (2015) 2, 4 389-401
a=7.0700(9)Å b=12.7624(13)Å c=14.977(2)Å
α=90.00° β=90.00° γ=90.00°
C6H6BrNO2S,C5H9NO
C6H6BrNO2S,C5H9NO
IUCrJ (2015) 2, 4 389-401
a=25.914(3)Å b=6.8687(9)Å c=19.202(2)Å
α=90.00° β=126.873(2)° γ=90.00°
C7H9NO2S,C5H9NO
C7H9NO2S,C5H9NO
IUCrJ (2015) 2, 4 389-401
a=5.210(3)Å b=8.449(4)Å c=16.104(8)Å
α=82.894(8)° β=82.798(8)° γ=81.772(8)°
C6H6ClNO2S,C5H9NO
C6H6ClNO2S,C5H9NO
IUCrJ (2015) 2, 4 389-401
a=10.521(2)Å b=13.7661(12)Å c=10.3407(16)Å
α=90.00° β=116.31(2)° γ=90.00°
C6H7NO2S,C5H9NO
C6H7NO2S,C5H9NO
IUCrJ (2015) 2, 4 389-401
a=7.1043(5)Å b=12.7937(10)Å c=14.0302(16)Å
α=90.00° β=90.00° γ=90.00°
((E)-4-((3,5-Dichloro-2-Hydroxybenzylidene)amino)benzamide
C14H10Cl2N2O2
IUCrJ (2017) 4, 3
a=8.4492(7)Å b=9.1167(5)Å c=9.1545(8)Å
α=81.461(6)° β=77.033(7)° γ=80.551(6)°
((E)-4-((3,5-Dichloro-2-Hydroxybenzylidene)amino)benzamide
C14H10Cl2N2O2
IUCrJ (2017) 4, 3
a=8.3558(4)Å b=12.7516(9)Å c=13.0135(9)Å
α=78.050(6)° β=77.167(5)° γ=88.734(4)°
((E)-4-((3,5-Dichloro-2-Hydroxybenzylidene)amino)benzamide
C14H10Cl2N2O2
IUCrJ (2017) 4, 3
a=7.2798(9)Å b=13.2794(15)Å c=14.5473(9)Å
α=87.618(7)° β=80.816(7)° γ=75.707(10)°
((E)-4-((3,5-Dibromo-2-Hydroxybenzylidene)amino)benzamide
C14H10Br2N2O2
IUCrJ (2017) 4, 3
a=8.3928(7)Å b=9.2815(8)Å c=9.3877(8)Å
α=81.620(7)° β=75.049(7)° γ=81.589(7)°
((E)-4-((3,5-Dichloro-2-Hydroxybenzylidene)amino)benzamide
C14H10Cl2N2O2
IUCrJ (2017) 4, 3
a=7.4309(14)Å b=13.296(2)Å c=14.694(3)Å
α=87.600(6)° β=80.034(7)° γ=75.859(7)°
((E)-4-((3,5-Diiodo-2-Hydroxybenzylidene)amino)benzamide
C14H10I2N2O2
IUCrJ (2017) 4, 3
a=8.4678(6)Å b=9.6066(7)Å c=9.6522(7)Å
α=81.239(2)° β=84.450(2)° γ=72.336(2)°
Etoricoxib-adipic acid cocrystal
C18H15ClN2O2S,0.5(C6H10O4)
CrystEngComm (2016) 18, 16 2825
a=16.6417(18)Å b=5.4913(6)Å c=23.838(3)Å
α=90° β=98.603(2)° γ=90°
Etoricoxib-caprolactam dihydrate
2(C18H15ClN2O2S),C6H11NO,2(H2O)
CrystEngComm (2016) 18, 16 2825
a=12.552(3)Å b=12.574(3)Å c=14.989(3)Å
α=96.690(3)° β=114.553(2)° γ=90.099(3)°
Etoricoxib-gluraric acid cocrystal
C23H23ClN2O6S
CrystEngComm (2016) 18, 16 2825
a=11.8317(15)Å b=12.7266(16)Å c=15.772(2)Å
α=90° β=90.203(2)° γ=90°
Etoricoxib-suberic acid cocrystal hydrate
2(C18H15ClN2O2S),0.5(C8H14O4),2(H2O),O
CrystEngComm (2016) 18, 16 2825
a=12.2796(15)Å b=12.4817(10)Å c=14.8713(18)Å
α=95.187(8)° β=113.754(12)° γ=91.242(8)°
Etoricoxib-suberic acid cocrystal
C18H15ClN2O2S,C8H14O4
CrystEngComm (2016) 18, 16 2825
a=9.0238(3)Å b=10.1284(5)Å c=14.8544(9)Å
α=82.766(5)° β=77.640(4)° γ=85.386(4)°
Celecoxib-2-Pyrrolidinone
C17H14F3N3O2S,C4H7NO
CrystEngComm (2014) 16, 1 24
a=11.0368(5)Å b=8.6083(4)Å c=12.0762(6)Å
α=90.00° β=109.049(5)° γ=90.00°
Celecoxib-Aza-2-cyclooctanone
C17H14F3N3O2S,C7H13NO
CrystEngComm (2014) 16, 1 24
a=8.0409(5)Å b=27.2426(18)Å c=11.7927(8)Å
α=90.00° β=105.806(7)° γ=90.00°
Celecoxib-Caprolactam
C17H14F3N3O2S,C6H11NO
CrystEngComm (2014) 16, 1 24
a=11.7189(11)Å b=8.7409(6)Å c=12.0503(10)Å
α=90.00° β=103.353(10)° γ=90.00°
Celecoxib-Valerolactam-Form-I
C17H14F3N3O2S,C5H9NO
CrystEngComm (2014) 16, 1 24
a=8.7346(6)Å b=11.2689(10)Å c=12.2391(9)Å
α=81.622(7)° β=87.560(6)° γ=73.363(7)°
Celecoxib-Valerolactam-Form-II
C17H14F3N3O2S,C5H9NO
CrystEngComm (2014) 16, 1 24
a=22.591(2)Å b=8.6211(8)Å c=23.814(2)Å
α=90.00° β=102.1630(10)° γ=90.00°
Celecoxib-Valerolactam-Form-III
C17H14F3N3O2S,C6H11NO
CrystEngComm (2014) 16, 1 24
a=14.8501(18)Å b=8.4190(11)Å c=17.761(2)Å
α=90.00° β=93.901(2)° γ=90.00°
C6H6ClNO2S,C5H9NO
C6H6ClNO2S,C5H9NO
IUCrJ (2015) 2, 4 389-401
a=25.701(4)Å b=6.8096(4)Å c=19.177(3)Å
α=90.00° β=127.40(2)° γ=90.00°
Lamotrigine cinnamic acid salt cocrystal
C9H7.34Cl2N5,C9H7.66O2
Crystal Growth & Design (2015) 15, 12 5816
a=17.5729(18)Å b=7.8008(8)Å c=14.8637(15)Å
α=90° β=113.662(2)° γ=90°
Lamotrigine-vanilline cocrystal
C9H7Cl2N5,C8H8O3
Crystal Growth & Design (2015) 15, 12 5816
a=10.7918(9)Å b=13.6805(12)Å c=13.8215(12)Å
α=90° β=110.5040(10)° γ=90°
Lamotriginium-salicylate acetonitrile solvate
C9H8Cl2N5,C7H5O3,C2H3N
Crystal Growth & Design (2015) 15, 12 5816
a=8.8408(5)Å b=10.9916(6)Å c=12.1332(5)Å
α=111.359(4)° β=111.196(5)° γ=93.988(5)°
Clotrimazole-2,5-Dihydroxybenzoic acid
C22H18ClN2,C7H5O4
Crystal Growth & Design (2015) 15, 5 2493
a=10.1762(10)Å b=10.6463(8)Å c=13.0417(9)Å
α=108.469(7)° β=102.963(8)° γ=107.069(8)°
Clotrimazole-Caffeic acid-anisole
C23H17ClN2,C9H7O4,C7H8O
Crystal Growth & Design (2015) 15, 5 2493
a=12.4974(17)Å b=14.527(2)Å c=17.789(2)Å
α=90.00° β=96.028(2)° γ=90.00°
Clotrimazole-2,4,6-Trihydroxybenzoic acid
C22H18ClN2,C7H5O5
Crystal Growth & Design (2015) 15, 5 2493
a=12.0214(14)Å b=13.8128(16)Å c=15.9926(18)Å
α=90.00° β=97.934(2)° γ=90.00°
Clotrimazole-Adipic acid
C22H17ClN2,0.5(C6H10O4)
Crystal Growth & Design (2015) 15, 5 2493
a=8.7300(9)Å b=9.6543(9)Å c=13.2542(13)Å
α=74.480(9)° β=84.281(8)° γ=85.466(8)°
Acedapsone
C16H16N2O4S
Crystal Growth & Design (2014) 14, 10 5260
a=8.2728(8)Å b=7.8636(8)Å c=23.762(2)Å
α=90.00° β=96.295(2)° γ=90.00°
Acedapsone
C16H16N2O4S
Crystal Growth & Design (2014) 14, 10 5260
a=24.519(3)Å b=8.0444(7)Å c=16.2501(15)Å
α=90.00° β=105.767(2)° γ=90.00°
Clotrimazole-p-Coumaric acid
C22H18ClN2,C9H7O3
Crystal Growth & Design (2015) 15, 5 2493
a=10.3536(13)Å b=14.9452(14)Å c=16.4976(19)Å
α=90.00° β=90.00° γ=90.00°